Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 568

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 568
---
 from joint ventures.
As of December 31, 2024, we had commitments for capital expenditures of approximately $3.1 million, primarily for the renovation of our new manufacturing facility in Shanghai, which is in the final stages of completion. We expect to fund these capital expenditures through cash flows from operations, bank borrowings and existing cash resources.
Our non-consolidated joint venture Shanghai Hutchison Pharmaceuticals had capital expenditures of $2.3 million, $6.5 million and $4.5 million for the years ended December 31, 2022, 2023 and 2024, respectively. These capital expenditures were primarily related to the renovation of new office and improvements to its production facilities in Shanghai. These capital expenditures were primarily funded through cash flows from operations of Shanghai Hutchison Pharmaceuticals.
C.Research and Development, Patents and Licenses, etc.
Full details of our research and development activities and expenditures are given in the “Business” and “Operating and Financial Review and Prospects” sections of this annual report above.
D.Trend Information.
Other than as described elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material adverse effect on our revenue, income, profitability, liquidity or capital resources, or that would cause our reported financial information not necessarily to be indicative of future operation results or financial condition.
E.Critical Accounting Estimates.
For information on our critical accounting estimates, please see “Operating Results—Critical Accounting Policies and Significant Judgments and Estimates” section of this annual report above.
​